临床试验/NCT01826370

NCT01826370终止不适用

A Post-Marketing Surveillance Study on the Safety, Tolerability and Efficacy of Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus

Boehringer Ingelheim51 个研究点分布在 1 个国家目标入组 678 人开始时间: 2012年5月最近更新: 2014年9月18日

适应症

干预措施

试验速览

阶段: 不适用
状态: 终止
发起方: Boehringer Ingelheim
入组人数: 678
试验地点: 51
主要终点: Frequency of Adverse Events and Serious Adverse Events

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is a prospective, non-interventional, open label, multi center, post marketing surveillance study designed to assess the safety, tolerability and efficacy of Linagliptin among Filipino patients with type 2 Diabetes Mellitus (DM) within the study duration of 24 weeks.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究组 & 干预措施

Linagliptin

干预措施: Linagliptin (Drug)

结局指标

主要结局

Frequency of Adverse Events and Serious Adverse Events

时间窗: Week 24

Frequency of adverse events and serious adverse events in an actual clinical setting, including hypoglycemic events.

次要结局

Change From Baseline to Week 24 of HbA1c(Baseline and 24 weeks)
Change From Baseline to Week 24 of Fasting Blood Sugar(Baseline and 24 weeks)

研究者

发起方

Boehringer Ingelheim

申办方类型

Industry

责任方

Sponsor

研究点 (51)

Loading locations...

相似试验

终止

不适用

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckUnresectable Locally Advanced Squamous Cell Carcinoma of Head and NeckLA SCCHN

NCT01303237Merck KGaA, Darmstadt, Germany88

已完成

4 期

Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean ChildrenHaemophilus Influenzae Type B Infection

NCT01404962Novartis Vaccines764

已完成

不适用

A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)Relapsing-Remitting Multiple Sclerosis

NCT01142492Merck KGaA, Darmstadt, Germany403

已完成

不适用

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical PracticeHIV Infections

NCT01524900Boehringer Ingelheim398

已完成

不适用

Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®Breast Neoplasm

NCT03445637Pfizer552